Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MSFT$554.19+35.02(+6.72%)UK Stocks-Factors to watch on November 512:52:05 AM ETMSFT$554.19+35.02(+6.72%)UPDATE 1-Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:44:24 AM ETBRK.A$869,300.76+32,855.63(+3.93%)Berkshire Hathaway: The Easy Re-Rating Is Gone12:39:39 AM ETMSFT$554.19+35.02(+6.72%)Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:11:41 AM ETMSFT$554.19+35.02(+6.72%)BRIEF-Microsoft Rejects Multibillion-Dollar AI Deal With UK's Nscale - FT12:11:33 AM ETMSFT$554.19+35.02(+6.72%)Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:09:40 AM ETTM$205.56+6.45(+3.34%)Toyota profit surges 34%, first rise in six quarters12:02:07 AM ETC$124.58+1.89(+1.54%)UPDATE 1-Oil falls for a fourth day on expectations for lower risk of Iran war escalation11:59:47 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Makes Its Biggest Move Yet Against Telecom Giants With Qualcomm 5G Deal: Elon Musk Hails QCOM's Technology, Calls It 'Excellent'11:59:02 PM ETMCD$278.93+17.15(+6.52%)McDonald's: 3 Key Takeaways for Long-Term Investors11:46:01 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Just Picked Qualcomm for Its Own 5G Network. I Still See the Stock as a Hold.11:41:01 PM ETIONQ$29.52-0.48(-1.60%)IonQ vs. SoundHound AI: Which Technology Stock Is a Better Buy for 2027?11:30:01 PM ETQCOM$160.25+8.76(+5.33%)Qualcomm Q4 Earnings Call Highlights11:27:00 PM ETAMD$485.27+4.95(+1.02%)AMD Stock Jumped After Its Report. I'd Wait for a Lower Price to Buy.11:17:01 PM ETGOOG$288.55+9.01(+3.24%)Google expands voluntary buyouts to 5 countries as AI spending fuels cost cuts11:16:50 PM ETSHOP$153.05+10.32(+7.23%)Shopify: 3 Key Takeaways for Long-Term Investors10:59:40 PM ETMCD$278.93+17.15(+6.52%)Why McDonald's Stock Popped Today10:45:31 PM ETMETA$630.20+8.87(+1.43%)Meta President Says Midterm Results Will Make Building Data Centers Harder10:11:00 PM ETPANW$348.32-2.07(-0.59%)BRIEF-Palo Alto Networks In Talks To Pay $500 Million For AI Security Startup Clutch Security - The Information9:57:31 PM ETMSFT$554.19+35.02(+6.72%)US STOCKS-Wall Street ends higher after Democrats win Congress; data center stocks tumble9:41:58 PM ETASML$1,479.73-72.05(-4.64%)ASML vs. Marvell Technology: Which Artificial Intelligence Stock Is a Better Buy Going into 2027?9:33:56 PM ETABT$115.40+6.10(+5.58%)DIARY-India economic, corporate events on November 59:00:32 PM ETNVO$41.87+1.67(+4.15%)Novo Nordisk: 3 Key Takeaways for Long-Term Investors8:55:55 PM ETAAPL$350.78+17.87(+5.39%)Apple is reportedly cutting budgets for its internal AI usage8:26:22 PM ET

TLX · NASDAQ

Telix Pharmaceuticals Limited

$9.77 +0.64 (+7.09%)

Company overview

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.3B
Employees
1,120
Headquarters
North Melbourne, VIC
Website
telixpharma.com
CEO
Christian Behrenbruch
Listed
November 14, 2024
P/E
79.30
Dividend yield
0.00%

Company financials

Revenue
$2B
Gross profit
$1.1B
Operating income
$108M
EBITDA
$155M
Net income
$39.2M
EPS
$0.12
Total assets
$1.8B
Total debt
$784M
Gross margin
56.36%
Net margin
1.96%
Earnings yield
1.26%

Revenue segmentation

By product (FY 2025)

No product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

8.519.7110.9012.0913.29
TLX 1D NASDAQ O9.43H9.67L9.36C9.67+0.64 (+7.09%)Vol501.80K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
TLXTelix Pharmaceuticals Limited Press release Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics PR Newswire
TLXTelix Pharmaceuticals Limited Stock news Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push MarketBeat
TLXTelix Pharmaceuticals Limited Press release Telix Reports Third Quarter 2026 Financial Performance GlobeNewswire
TLXTelix Pharmaceuticals Limited Press release Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix GlobeNewswire
TLXTelix Pharmaceuticals Limited Press release Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. GlobeNewswire
TLXTelix Pharmaceuticals Limited Press release Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented. PR Newswire
TLXTelix Pharmaceuticals Limited Stock news First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) GlobeNewswire
TLXTelix Pharmaceuticals Limited Press release IBA and Telix strengthen ties through agreement to GlobeNewswire
TLXTelix Pharmaceuticals Limited Stock news Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade Zacks Investment Research
TLXTelix Pharmaceuticals Limited Stock news Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript Seeking Alpha
TLXTelix Pharmaceuticals Limited Stock news Telix Pharmaceuticals Limited (TLX) M&A Call Transcript Seeking Alpha
TLXTelix Pharmaceuticals Limited Stock news Crude Oil Down 4%; Intel Shares Move Higher Benzinga
TLXTelix Pharmaceuticals Limited Stock news Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session Benzinga
TLXTelix Pharmaceuticals Limited Press release Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse PR Newswire
TLXTelix Pharmaceuticals Limited Press release Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse GlobeNewswire
TLXTelix Pharmaceuticals Limited Stock news Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement Seeking Alpha
TLXTelix Pharmaceuticals Limited Stock news Radiant Logistics, Waystar, Forgent Power Solutions And Other Big Stocks Moving Higher On Tuesday Benzinga
TLXTelix Pharmaceuticals Limited Stock news Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
TLXTelix Pharmaceuticals Limited Stock news FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug Benzinga
TLXTelix Pharmaceuticals Limited Press release FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara GlobeNewswire
See more
FAQ

Questions about Telix Pharmaceuticals Limited

What does Telix Pharmaceuticals Limited do?
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
What is TLX's market cap?
Telix Pharmaceuticals Limited (TLX) is a listed stock with a live quote. The latest market cap on this page is $3.3B.
Where is Telix Pharmaceuticals Limited headquartered?
Telix Pharmaceuticals Limited is headquartered in North Melbourne, VIC.
How do I get TLX news from the API?
Call GET /v1/news?tickers=TLX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does TLX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for TLX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the TLX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs